Form 4: BridgeBio Pharma CFO Brian Stephenson Reports Stock Transactions

Brian Stephenson, CFO of BridgeBio Pharma, reported the acquisition of 25,799 shares and the disposal of 13,077 shares to cover tax obligations related to vesting restricted stock units.

Summary

• Brian Stephenson, the CFO of BridgeBio Pharma, has reported transactions involving the company's stock.
• On November 16, 2024, Stephenson acquired 25,799 shares of common stock through the vesting of restricted stock units.
• He also disposed of 13,077 shares of common stock at a price of $23.72 per share to cover tax obligations related to the vesting of the restricted stock units.
• Additionally, Stephenson acquired 778, 947, 17,369, and 6,705 restricted stock units, which vest over time.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing of stock transactions by a company executive, and does not indicate any positive or negative sentiment.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It provides transparency into the stock ownership of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The vesting schedules of the restricted stock units are typical for executive compensation packages in the biotech industry.
• The tax withholding process is a common practice when restricted stock units vest.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation and tax obligations.

Key Dates

Keywords

stock transactions, restricted stock units, insider trading, Form 4, BridgeBio Pharma, BBIO, CFO, Brian Stephenson